ZYNLONTA Drug Insight and Market Forecast - 2032

This “ZYNLONTA Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ZYNLONTA for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the ZYNLONTA for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ZYNLONTA for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZYNLONTA market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary

ZYNLONTA (loncastuximab tesirine) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD)-dimer toxin. Once bound to a CD19-expressing cell, ADCT-402 is internalized into the cell, where enzymes release the PBD-based warhead. CD19 is an ideal target for an ADC approach, as it is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia, while its expression in healthy tissue is restricted. The monoclonal IgG1 kappa antibody component binds to human CD19; a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer, and an alkylating agent. Upon binding to CD19, loncastuximab tesirine-lpyl is internalized, followed by the release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had anticancer activity in animal models of lymphoma. ZYNLONTA is indicated for treating adult patients with R/R large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL, not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on the overall response rate.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ZYNLONTA description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on ZYNLONTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZYNLONTA research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ZYNLONTA.
• The report contains forecasted sales of ZYNLONTA for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for ZYNLONTA in DLBCL.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publishing team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZYNLONTA Analytical Perspective

In-depth ZYNLONTA Market Assessment

This report provides a detailed market assessment of ZYNLONTA for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ZYNLONTA Clinical Assessment

The report provides the clinical trials information of ZYNLONTA for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNLONTA dominance.
• Other emerging products for DLBCL are expected to give tough market competition to ZYNLONTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYNLONTA in DLBCL.
• Our in-depth analysis of the forecasted sales data of ZYNLONTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZYNLONTA in DLBCL.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ZYNLONTA?
• What is the clinical trial status of the study related to ZYNLONTA in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYNLONTA development?
• What are the key designations that have been granted to ZYNLONTA for DLBCL?
• What is the forecasted market scenario of ZYNLONTA for DLBCL?
• What are the forecasted sales of ZYNLONTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ZYNLONTA for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

This product will be delivered within 2 business days.